The recent withdrawal of rofecoxib (Vioxx) from the market has intensified controversy about the safety of cyclooxygenase (COX)-2 inhibitors. Results from several recently published studies address ...
Toronto, ON - A new retrospective cohort study has found no increase in the short-term risk of AMI among elderly users of COX-2 inhibitors, nor did it find any evidence of a cardioprotective effect of ...
Cyclooxygenase-2 (COX-2) inhibitors have long been employed to modulate inflammatory responses in a range of conditions, from arthritis to malignancies. In recent years, the convergence of ...
UPSTREAM, DOWNSTREAM: Biochemical activity upstream of cyclooxygenase is better understood than reactions downstream of the enzyme. Cancer, Alzheimer's disease, and stroke represent disparate ...
Ferroptosis plays an essential role in chronic liver diseases, and cyclooxygenase-2 (COX-2) affects liver fibrosis through multiple mechanisms. However, research on COX-2 regulation of ferroptosis in ...
NEW YORK, July 18 (Praxis Press) A new class of nonsteroidal anti-inflammatory drugs selectively inhibits cyclooxygenase (COX)-2 and may produce fewer adverse effects than nonselective inhibitors.
Scientists say combining a low-dose of THC with a common anti-inflammatory drug improved cognition and reduced Alzheimer’s-related brain changes in mice.
Augusta University has patented NSAID derivatives acting as prostaglandin G/H synthase 1 (PTGS1; COX-1) and/or COX-2 inhibitors potentially useful for the treatment of inflammation and pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results